Executive Director, Dale O’Brien, MD, reports, “there appears to be a subtype of pancreatic cancer, about 15%, that can be identified through genetic testing. The important point is that patients in this group often do better with different treatment agents than with more standard therapy.”
The nonprofit indicates that there are now 30-gene cancer panel saliva tests that can be obtained for less than $250. These tests are not exhaustive but represent a feasible and affordable reasonable current step forward. More comprehensive genetic testing measures are also a viable option. Read more . . .